<DOC>
	<DOCNO>NCT01514461</DOCNO>
	<brief_summary>The purpose study determine whether LCQ908 effective safe lower triglycerides subject Familial Chylomicronemia Syndrome ( FCS ) ( Hyperlipoproteinemia [ HLP ] type I ) . Data study use support registration submission LCQ908 20 mg 40 mg treatment chylomicronemia subject FCS ( HLP Type 1 ) .</brief_summary>
	<brief_title>A Randomized , Double-blind , Placebo Controlled Study Assess Efficacy , Safety Tolerability LCQ908 Subjects With Familial Chylomicronemia Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type I</mesh_term>
	<criteria>Key 1 . Written informed consent give assessment perform Period I . 2 . Male female patient age least 18 year age . 3 . Fasting triglyceride ≥ 8.4 mmol/L ( 750 mg/dL ) Screening . 4 . An establish diagnosis FCS ( HLP Type I ) confirm ultracentrifugation document medical history fast triglyceride ≥ 8.4 mmol/L ( 750 mg/dL ) documentation follow Screening Screening Period : Confirmed homozygote compound heterozygote know lossoffunction mutation Type Icausing gene ( LPL , apo C II , GPIHBP1 , LMF1 ) Post heparin plasma LPL activity ≤ 20 % normal Confirmed presence LPL inactivate antibody 5 . History pancreatitis . Key 1 . Current pancreatitis , pancreatitis require inactive least 1 week prior screen Visit . 2 . Treatment fish oil preparation within 4 week prior randomization . 3 . Treatment bile acid binding resin ( i.e. , colesevelam , etc . ) within 4 week prior randomization . 4 . Treatment fibrates within 4 week prior randomization . 5 . Glybera [ alipogene tiparvovec ( AAV1LPLS447X ) ] gene therapy exposure within two year prior screen . 6 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 7 . Any surgical medical condition , acute unstable chronic disease may , base investigator 's opinion , jeopardize patient case participation study might significantly alter absorption , distribution , metabolism excretion study drug . 8 . History drug alcohol abuse within 12 month prior randomization evidence abuse screen . 9 . Evidence liver disease liver injury indicate abnormal liver function test aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) , serum bilirubin . 10 . Estimated glomerular filtration rate ( eGFR ) &lt; 30mL/min/1.73m2 history chronic renal disease . 11 . Participation clinical investigation within four ( 4 ) week prior initial dose longer require local regulation , limitation participation base local regulation . 12 . History hypersensitivity study drug drug similar chemical class . 13 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive HCG laboratory test . 14 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 100 day discontinuation investigational study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hyperlipoproteinemia ( HLP Type I )</keyword>
	<keyword>Fasting Triglycerides</keyword>
</DOC>